RxDoctor Payments Data

Ashley Frith, MD

Medical Oncology · Saint Peters, MONPI 1730352014

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $9,673 of the $14,497 with a category attached, or 66.7%. 14 manufacturers reported payments, led by Gilead at 57.4% of the total.

$14,497in general payments, 2019–2025

Across 78 payments — averaging $185.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$8K
  • AstraZeneca$3K
  • Novartis$1K
  • Daiichi Sankyo Inc.$1K
  • Lilly USA, LLC$262
  • Covis Pharma GmbH$200
  • plus $703 from 8 others
$2,774,816in research payments, 2019–2025

Across 213 payments — averaging $13,027 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$1M
  • Seagen Inc.$1M
  • Daiichi Sankyo Inc.$234K
  • Merck$167K
  • AstraZeneca$153K
  • Eli Lilly$145K
  • plus $19K from 1 others

What the payments were for

  • Consulting fees$9,67367%
  • Speaking & faculty fees$5504%
  • Travel & lodging$1,48810%
  • Food & beverage$2,68519%
  • Education$1021%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,497 in reported general payments places this provider in the 70th percentile of 144 medical oncology providers in Missouri.

See all medical oncology providers in Missouri

Medicare billing

Part B allowed, 2024
$2,703,098
Medicare patients
466
Services billed
94,647

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib44$729,630
OrserduElacestrant Hcl19$430,464
XareltoRivaroxaban71$51,097
EliquisApixaban44$37,379
Exemestane93$16,060
Letrozole763$14,340
Anastrozole188$2,233
Tamoxifen Citrate69$1,618
Prochlorperazine Maleate67$1,246
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen40$1,139
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen11$811
Gabapentin61$737
Dexamethasone65$594
Oxybutynin Chloride45$536
Hydroxyurea15$440

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Stemline Therapeutics Inc.Orserdu$100$430,46419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 144 medical oncology providers in Missouri.

Other medical oncology in Saint Peters

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →